GarcÃa-Hernández A et al. |
High glucose concentrations alter the biomineralization process in human osteoblastic cells. |
2012 |
Bone |
pmid:22086137
|
Chao TH et al. |
Opposite associations of osteoprotegerin and ZBTB40 polymorphisms with bone mineral density of the hip in postmenopausal Taiwanese women. |
2012 |
J Chin Med Assoc |
pmid:22824048
|
Terpos E et al. |
Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. |
2011 Nov-Dec |
Clin. Exp. Rheumatol. |
pmid:22032557
|
Arikan F et al. |
C-telopeptide pyridinoline crosslinks of type I collagen, soluble RANKL, and osteoprotegerin levels in crevicular fluid of dental implants with peri-implantitis: a case-control study. |
2011 Mar-Apr |
Int J Oral Maxillofac Implants |
pmid:21483881
|
Crespi R et al. |
Corticocancellous porcine bone in the healing of human extraction sockets: combining histomorphometry with osteoblast gene expression profiles in vivo. |
2011 Jul-Aug |
Int J Oral Maxillofac Implants |
pmid:21841997
|
Franke S et al. |
Advanced glycation end products affect growth and function of osteoblasts. |
2011 Jul-Aug |
Clin. Exp. Rheumatol. |
pmid:21906430
|
Rezg R et al. |
Inhibitors of vascular calcification as potential therapeutic targets. |
2011 Jul-Aug |
J. Nephrol. |
pmid:21688249
|
Reyes-GarcÃa R et al. |
[Cardiovascular disease and bone metabolism]. |
2011 Aug-Sep |
Endocrinol Nutr |
pmid:21775224
|
Wang Y et al. |
LC, a novel estrone-rhein hybrid compound, concurrently stimulates osteoprotegerin and inhibits receptor activator of NF-κB ligand (RANKL) and interleukin-6 production by human osteoblastic cells. |
2011 |
Mol. Cell. Endocrinol. |
pmid:21291955
|
Szulc P et al. |
Cortical bone status is associated with serum osteoprotegerin concentration in men: the STRAMBO study. |
2011 |
J. Clin. Endocrinol. Metab. |
pmid:21565793
|
Zhang M et al. |
EP1(-/-) mice have enhanced osteoblast differentiation and accelerated fracture repair. |
2011 |
J. Bone Miner. Res. |
pmid:20939055
|
Millard SM et al. |
Blockade of receptor-activated G(i) signaling in osteoblasts in vivo leads to site-specific increases in cortical and cancellous bone formation. |
2011 |
J. Bone Miner. Res. |
pmid:20939063
|
Zhang Y et al. |
Enhanced osteoclastic resorption and responsiveness to mechanical load in gap junction deficient bone. |
2011 |
PLoS ONE |
pmid:21897843
|
Tanaka H et al. |
Expression of RANKL/OPG during bone remodeling in vivo. |
2011 |
Biochem. Biophys. Res. Commun. |
pmid:21771583
|
Meulman T et al. |
Impact of Porphyromonas gingivalis inoculation on ligature-induced alveolar bone loss. A pilot study in rats. |
2011 |
J. Periodont. Res. |
pmid:21726226
|
Yang L et al. |
Osteoprotegerin and osteoprotegerin ligand expression during human marrow stromal cell differentiation and their effect on osteoclast formation. |
2011 |
Chin. Med. J. |
pmid:22088466
|
Reinhard H et al. |
Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria. |
2011 |
Cardiovasc Diabetol |
pmid:21801376
|
Gordon IK and Camphausen K |
Research highlights. |
2011 |
Biomark Med |
pmid:21861664
|
Jabbar S et al. |
Plasma vitamin D and cytokines in periodontal disease and postmenopausal osteoporosis. |
2011 |
J. Periodont. Res. |
pmid:20731767
|
Lossdörfer S et al. |
PTH(1-34)-induced changes in RANKL and OPG expression by human PDL cells modify osteoclast biology in a co-culture model with RAW 264.7 cells. |
2011 |
Clin Oral Investig |
pmid:20697756
|
Yang XY et al. |
[Influence of surface modification of titanium on OPG/RANKL mRNA expression in MG-63 human osteoblast-like cells]. |
2011 |
Nan Fang Yi Ke Da Xue Xue Bao |
pmid:21868322
|
Malliga DE et al. |
The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology - a review. |
2011 |
Wien Med Wochenschr |
pmid:21870142
|
Guo HL et al. |
[Experimental study on the mechanism of icariin improving human osteoblasts proliferation and the expression of OPG protein]. |
2011 |
Zhongguo Gu Shang |
pmid:21870401
|
McGrath EE |
OPG/RANKL/RANK pathway as a therapeutic target in cancer. |
2011 |
J Thorac Oncol |
pmid:21849854
|
Findlay DM and Atkins GJ |
Relationship between serum RANKL and RANKL in bone. |
2011 |
Osteoporos Int |
pmid:21850548
|
Harada S and Takahashi N |
[Control of bone resorption by RANKL-RANK system]. |
2011 |
Clin Calcium |
pmid:21814016
|
Nakamura M and Udagawa N |
[Osteoporosis and RANKL signal]. |
2011 |
Clin Calcium |
pmid:21814019
|
Persson E and Lerner UH |
The neuropeptide VIP regulates the expression of osteoclastogenic factors in osteoblasts. |
2011 |
J. Cell. Biochem. |
pmid:21815197
|
Üstündağ M et al. |
The role of serum osteoprotegerin and S-100 protein levels in patients with acute ischaemic stroke: determination of stroke subtype, severity and mortality. |
2011 |
J. Int. Med. Res. |
pmid:21819709
|
Christoforidis A et al. |
Comparative study of dual energy X-ray absorptiometry and quantitative ultrasonography with the use of biochemical markers of bone turnover in boys with haemophilia. |
2011 |
Haemophilia |
pmid:20825502
|
Shin M et al. |
The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells. |
2011 |
Carcinogenesis |
pmid:21890459
|
Grigoropoulou P et al. |
The role of the osteoprotegerin/RANKL/RANK system in diabetic vascular disease. |
2011 |
Curr. Med. Chem. |
pmid:21919846
|
Riancho JA and Delgado-Calle J |
[Osteoblast-osteoclast interaction mechanisms]. |
2011 |
Reumatol Clin |
pmid:21924211
|
Peng S et al. |
The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin. |
2011 |
Bone |
pmid:21925296
|
Fan R et al. |
Receptor activator of nuclear factor kappa B ligand and osteoprotegerin expression in chronic apical periodontitis: possible association with inflammatory cells. |
2011 |
Chin. Med. J. |
pmid:21933620
|
Osorio A et al. |
Mineral-bone metabolism markers in young hemodialysis patients. |
2011 |
Clin. Biochem. |
pmid:21933667
|
Nybo M et al. |
Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients. |
2011 |
Basic Clin. Pharmacol. Toxicol. |
pmid:21726411
|
Fradet A et al. |
Dual function of ERRα in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin. |
2011 |
Cancer Res. |
pmid:21734015
|
Ashley DT et al. |
Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects. |
2011 |
Metab. Clin. Exp. |
pmid:21087777
|
Campbell GM et al. |
Bone quality is partially recovered after the discontinuation of RANKL administration in rats by increased bone mass on existing trabeculae: an in vivo micro-CT study. |
2011 |
Osteoporos Int |
pmid:20480144
|
Tekkesin MS et al. |
The role of RANK/RANKL/OPG signalling pathways in osteoclastogenesis in odontogenic keratocysts, radicular cysts, and ameloblastomas. |
2011 |
Head Neck Pathol |
pmid:21643971
|
Jiang JQ et al. |
Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease-mineral and bone disorder. |
2011 |
Nephrology (Carlton) |
pmid:21649792
|
Choi EM |
Honokiol isolated from Magnolia officinalis stimulates osteoblast function and inhibits the release of bone-resorbing mediators. |
2011 |
Int. Immunopharmacol. |
pmid:21621646
|
Ueland T et al. |
Osteoprotegerin levels predict mortality in patients with symptomatic aortic stenosis. |
2011 |
J. Intern. Med. |
pmid:21623962
|
Wheater G et al. |
Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis. |
2011 |
Osteoporos Int |
pmid:21625887
|
Karadag-Saygi E et al. |
The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis. |
2011 |
Gynecol. Endocrinol. |
pmid:21627558
|
Taylor R et al. |
Osteoclast formation and function in pigmented villonodular synovitis. |
2011 |
J. Pathol. |
pmid:21706481
|
Conaway HH et al. |
Retinoids stimulate periosteal bone resorption by enhancing the protein RANKL, a response inhibited by monomeric glucocorticoid receptor. |
2011 |
J. Biol. Chem. |
pmid:21715325
|
El-Shehaby A et al. |
Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. |
2011 |
J. Clin. Immunol. |
pmid:21691937
|
Roshandel D et al. |
Influence of polymorphisms in the RANKL/RANK/OPG signaling pathway on volumetric bone mineral density and bone geometry at the forearm in men. |
2011 |
Calcif. Tissue Int. |
pmid:21964949
|
Davenport C et al. |
Identifying coronary artery disease in men with type 2 diabetes: osteoprotegerin, pulse wave velocity, and other biomarkers of cardiovascular risk. |
2011 |
J. Hypertens. |
pmid:21970938
|
Kanayama K et al. |
Osteoclast and osteoblast activities on carbonate apatite plates in cell cultures. |
2011 |
J Biomater Appl |
pmid:20624844
|
Ikeda K et al. |
Conditional expression of constitutively active estrogen receptor α in osteoblasts increases bone mineral density in mice. |
2011 |
FEBS Lett. |
pmid:21439958
|
Teramachi J et al. |
Adenosine abolishes MTX-induced suppression of osteoclastogenesis and inflammatory bone destruction in adjuvant-induced arthritis. |
2011 |
Lab. Invest. |
pmid:21339747
|
Katz J et al. |
Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. |
2011 |
Int J Oral Maxillofac Surg |
pmid:21396799
|
Cianciolo G et al. |
Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients. |
2011 |
Nephrol. Dial. Transplant. |
pmid:20659908
|
Bitto A et al. |
Genistein aglycone effect on bone loss is not enhanced by supplemental calcium and vitamin D3: a dose ranging experimental study. |
2011 |
Phytomedicine |
pmid:21397481
|
Di Bartolo BA et al. |
Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification. |
2011 |
Cardiovasc. Res. |
pmid:21447702
|
Ho TY et al. |
Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG), in rat adjuvant-induced arthritis. |
2011 |
Bone |
pmid:21419242
|
Chasseraud M et al. |
Tumor necrosis factor-related apoptosis-inducing ligand and vascular calcification. |
2011 |
Ther Apher Dial |
pmid:21426505
|
Duheron V et al. |
Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit. |
2011 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:21402940
|
Dimitrow PP et al. |
The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis. |
2011 |
J. Heart Valve Dis. |
pmid:21404893
|
Marques EA et al. |
Effects of resistance and aerobic exercise on physical function, bone mineral density, OPG and RANKL in older women. |
2011 |
Exp. Gerontol. |
pmid:21316442
|
Dimitriadis K et al. |
Exercise blood pressure response is related to asymmetric dimethylarginine and osteoprotegerin in hypertension. |
2011 |
Int. J. Cardiol. |
pmid:21975354
|
Yao Y et al. |
Synergistic enhancement of new bone formation by recombinant human bone morphogenetic protein-2 and osteoprotegerin in trans-sutural distraction osteogenesis: a pilot study in dogs. |
2011 |
J. Oral Maxillofac. Surg. |
pmid:22018252
|
Brown TT et al. |
Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. |
2011 |
Antivir. Ther. (Lond.) |
pmid:22024522
|
Mainini G et al. |
Serum osteoprotegerin correlates with age and bone mass in postmenopausal, but not in fertile age women. |
2011 |
Clin Exp Obstet Gynecol |
pmid:22268274
|
Yener S et al. |
Is there an association between non-functioning adrenal adenoma and endothelial dysfunction? |
2011 |
J. Endocrinol. Invest. |
pmid:20530985
|
Claro T et al. |
Staphylococcus aureus protein A binds to osteoblasts and triggers signals that weaken bone in osteomyelitis. |
2011 |
PLoS ONE |
pmid:21525984
|
Giro G et al. |
Influence of estrogen deficiency on bone around osseointegrated dental implants: an experimental study in the rat jaw model. |
2011 |
J. Oral Maxillofac. Surg. |
pmid:21530046
|
Won KY et al. |
RANK signalling in bone lesions with osteoclast-like giant cells. |
2011 |
Pathology |
pmid:21532526
|
Naot D et al. |
Molecular mechanisms involved in the mitogenic effect of lactoferrin in osteoblasts. |
2011 |
Bone |
pmid:21515435
|
Aydin H et al. |
Effect of oxidative stress on aorta and tibia osteoprotegerin gene expression in ovariectomized rats. |
2011 |
Minerva Endocrinol. |
pmid:21519319
|
Altinova AE et al. |
Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes. |
2011 |
Scand. J. Clin. Lab. Invest. |
pmid:21486111
|
Mercatali L et al. |
Bone metastases detection by circulating biomarkers: OPG and RANK-L. |
2011 |
Int. J. Oncol. |
pmid:21491082
|
Stein SH et al. |
Statins regulate interleukin-1β-induced RANKL and osteoprotegerin production by human gingival fibroblasts. |
2011 |
J. Periodont. Res. |
pmid:21463327
|
Liang QQ et al. |
The expression of osteoprotegerin is required for maintaining the intervertebral disc endplate of aged mice. |
2011 |
Bone |
pmid:21466864
|
Honda K |
Interleukin-6 and soluble interleukin-6 receptor suppress osteoclastic differentiation by inducing PGE(2) production in chondrocytes. |
2011 |
J Oral Sci |
pmid:21467819
|
Dimitri P et al. |
Adipokines, bone-derived factors and bone turnover in obese children; evidence for altered fat-bone signalling resulting in reduced bone mass. |
2011 |
Bone |
pmid:20932948
|
Yu H et al. |
Overexpression of osteoprotegerin promotes preosteoblast differentiation to mature osteoblasts. |
2011 |
Angle Orthod |
pmid:20936961
|
Palaniswamy C et al. |
Association of warfarin use with valvular and vascular calcification: a review. |
2011 |
Clin Cardiol |
pmid:21298649
|
Sipos W et al. |
OPG-Fc treatment in growing pigs leads to rapid reductions in bone resorption markers, serum calcium, and bone formation markers. |
2011 |
Horm. Metab. Res. |
pmid:22161252
|
Akinci B et al. |
Increased osteoprotegerin levels in women with previous gestational diabetes developing metabolic syndrome. |
2011 |
Diabetes Res. Clin. Pract. |
pmid:20970873
|
Toffoli B et al. |
Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. |
2011 |
Mol. Cell. Endocrinol. |
pmid:20832449
|
Tang T et al. |
Effect of water-soluble P-chitosan and S-chitosan on human primary osteoblasts and giant cell tumor of bone stromal cells. |
2011 |
Biomed Mater |
pmid:21205994
|
Attia EA et al. |
Assessment of osteoporosis in psoriasis with and without arthritis: correlation with disease severity. |
2011 |
Int. J. Dermatol. |
pmid:21182499
|
Sun Z and Tee BC |
Molecular variations related to the regional differences in periosteal growth at the mandibular ramus. |
2011 |
Anat Rec (Hoboken) |
pmid:21157918
|
Cannon JG et al. |
Follicle-stimulating hormone promotes RANK expression on human monocytes. |
2011 |
Cytokine |
pmid:21159522
|
Choe JY et al. |
Radiographic bone damage in chronic gout is negatively associated with the inflammatory cytokines soluble interleukin 6 receptor and osteoprotegerin. |
2011 |
J. Rheumatol. |
pmid:21159831
|
Mahoney DJ et al. |
TSG-6 inhibits osteoclast activity via an autocrine mechanism and is functionally synergistic with osteoprotegerin. |
2011 |
Arthritis Rheum. |
pmid:21162099
|
Čolović M et al. |
FGF-R3 and OPG expression in patient with multiple myeloma following systemic sclerosis: case report and review of the literature. |
2011 |
Int. J. Hematol. |
pmid:21207214
|
Hashiguchi D et al. |
Mineral trioxide aggregate solution inhibits osteoclast differentiation through the maintenance of osteoprotegerin expression in osteoblasts. |
2011 |
J Biomed Mater Res A |
pmid:21171155
|
Eslami B et al. |
Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate. |
2011 |
Calcif. Tissue Int. |
pmid:21327765
|
Jørgensen L et al. |
Serum osteoprotegerin levels are related to height loss: the Tromsø Study. |
2011 |
Eur. J. Epidemiol. |
pmid:21331661
|
Yuan H et al. |
Receptor activator of nuclear factor kappa B ligand antagonists inhibit tissue inflammation and bone loss in experimental periodontitis. |
2011 |
J. Clin. Periodontol. |
pmid:22092474
|
Garcia VG et al. |
Treatment of experimental periodontal disease with antimicrobial photodynamic therapy in nicotine-modified rats. |
2011 |
J. Clin. Periodontol. |
pmid:22092666
|
Santini D et al. |
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. |
2011 |
PLoS ONE |
pmid:21559440
|
Hen K et al. |
[Osteoprotegerin--a new atherosclerosis marker]. |
2011 |
Pol. Merkur. Lekarski |
pmid:22097184
|
Mariúba MV et al. |
Effect of triiodothyronine on the maxilla and masseter muscles of the rat stomatognathic system. |
2011 |
Braz. J. Med. Biol. Res. |
pmid:21584440
|
Tang Y et al. |
Porphyromonas endodontalis lipopolysaccharides induce RANKL by mouse osteoblast in a way different from that of Escherichia coli lipopolysaccharide. |
2011 |
J Endod |
pmid:22099899
|